Matches in Nanopublications for { ?s ?p "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP337800.RACqRKI-khDVchYi6e01rdPzhwycTkawo9-ganjegWFYA130_assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP337800.RACqRKI-khDVchYi6e01rdPzhwycTkawo9-ganjegWFYA130_provenance.
- assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP876126.RAB5NCxnDeA37OFpP80Tnpvcda2OFf5h26Bw_iROu6a68130_assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP876126.RAB5NCxnDeA37OFpP80Tnpvcda2OFf5h26Bw_iROu6a68130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.